Choline Salicylate

Summary

Choline Salicylate (CHEMBL2104095) is an approved small molecule (ATC N02BA03); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BA03
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 241.28 Da · C12H19NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104095
Name	Choline Salicylate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54686350
ATC	N02BA03
Molecular formula	C12H19NO4
Molecular weight	241.28
InChIKey	UDKCHVLMFQVBAA-UHFFFAOYSA-M

SMILES: C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-]

IUPAC name: 2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium

Also known as: Choline salicylate, Choline salicylic acid salt, Choline subsalicylate, Choline, salicylate (salt), Dinnefords, Salicilato de colina, Salicylate de choline, Salicylic acid choline salt, CHOLINE SALICYLATE

Patent coverage: 2,412 distinct patent families (8,779 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 8,770 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4).

The 2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04640779	PHASE1	COMPLETED	Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
NCT06531720	Not specified	COMPLETED	Comparison of the Effects of Oral Ulceration Healing in Patients Wearing a Removable Denture

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).